medrxiv Subject Collection: Pain Medicine Palliative Medicine
http://medrxiv.org
This feed contains articles for medRxiv Subject Collection "Pain Medicine Palliative Medicine"
medrxivmedrxivhttps://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png
http://medrxiv.org
<![CDATA[
Pain on the Street: Implementation of a Field-Based Pain Response for People Experiencing Homelessness
]]>
https://www.medrxiv.org/content/10.64898/2026.08.13.26360409v1?rss=1
2026-08-17doi:10.64898/2026.08.13.26360409Cold Spring Harbor Laboratory2026-08-17
<![CDATA[
Pain and Pain Sensitivity Assessments in the Acute to Chronic Pain Signatures (A2CPS) Program
]]>
https://www.medrxiv.org/content/10.64898/2026.08.14.26360457v1?rss=1
2026-08-17doi:10.64898/2026.08.14.26360457Cold Spring Harbor Laboratory2026-08-17
<![CDATA[
The implementation of a falls observational tool and its clinical effectiveness of reducing falls in a palliative care setting: a mixed methods study
]]>
https://www.medrxiv.org/content/10.64898/2026.08.13.26360364v1?rss=1
2026-08-14doi:10.64898/2026.08.13.26360364Cold Spring Harbor Laboratory2026-08-14
<![CDATA[
Relevance Based Prediction: A Transparent, Non-Artificial Intelligence, Mathematical Solution to Personalized Opioid Treatment
]]>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359966v1?rss=1
2026-08-10doi:10.64898/2026.08.07.26359966Cold Spring Harbor Laboratory2026-08-10
<![CDATA[
Targeted Pulsed Radio Frequency (PRF) Stimulation in the Management of Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Placebo-Controlled Trial
]]>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359945v1?rss=1
2026-08-10doi:10.64898/2026.08.07.26359945Cold Spring Harbor Laboratory2026-08-10
<![CDATA[
Development of an interdisciplinary network to improve the capacity to conduct digital legacy research: a quality improvement initiative
]]>
https://www.medrxiv.org/content/10.64898/2026.08.06.26359876v1?rss=1
2026-08-10doi:10.64898/2026.08.06.26359876Cold Spring Harbor Laboratory2026-08-10
<![CDATA[
Neural Alterations in Chronic Pain: MRI Analysis
]]>
https://www.medrxiv.org/content/10.64898/2026.08.05.26359702v1?rss=1
2026-08-07doi:10.64898/2026.08.05.26359702Cold Spring Harbor Laboratory2026-08-07
<![CDATA[
Biobehavioral pain profiling of minoritized adults with chronic widespread pain and clinical obesity before and after bariatric surgery: study protocol for a longitudinal, observational cohort study
]]>
https://www.medrxiv.org/content/10.64898/2026.08.04.26359660v1?rss=1
2026-08-06doi:10.64898/2026.08.04.26359660Cold Spring Harbor Laboratory2026-08-06
<![CDATA[
Multidimensional symptom burden across sleep, pain, affect, cognition and energy: cross-sectional associations with chronic pain interference and work disability in UK Biobank
]]>
https://www.medrxiv.org/content/10.64898/2026.08.03.26359604v1?rss=1
2026-08-05doi:10.64898/2026.08.03.26359604Cold Spring Harbor Laboratory2026-08-05
<![CDATA[
Pain-Reporting Variability and Reliability as Predictors of Placebo Effects: A Cross-Sectional Experimental Pain Study
]]>
https://www.medrxiv.org/content/10.64898/2026.07.31.26359372v1?rss=1
2026-08-03doi:10.64898/2026.07.31.26359372Cold Spring Harbor Laboratory2026-08-03
<![CDATA[
Analgesic Efficacy of Native Himalayan Shilajit as Add-On Therapy in Myofascial Pain Syndrome: An Exploratory Pilot Clinical Trial
]]>
https://www.medrxiv.org/content/10.64898/2026.07.24.26357716v1?rss=1
4 were enrolled. Native Himalayan Shilajit 250 mg daily was administered as add-on therapy for 49 days. The main outcome was the percentage of participants with [≥]30% VAS reduction at Day 49. The intensity of pain, the dose of analgesics consumed and the number of trigger points were evaluated at five time points (Day 0, 12, 24, 36, 49). Throughout, adverse events were monitored.
RESULTSOf 80 enrolled participants, 76 (95.0%) completed the per-protocol analysis. Mean age was 41.25 {+/-} 9.05 years; 52.6% were male. A total of 56 of 76 participants (73.7%; 95% CI: 62.1- 82.8%) achieved the primary endpoint. Mean VAS score declined from 6.63 {+/-} 1.08 at baseline to.63 {+/-} 1.72 at Day 49 (mean reduction 45.3%; Friedman {chi}2 = 278.5, p<0.001). The first signs of pain reduction were seen at Day 24. The number of analgesic doses consumed decreased by 75.5% during the study period ({chi}2 = 126.1, p<0.001). There was a significant reduction in trigger point count from baseline to Day 49 (p=0.031) of 23.4%. One Grade 2 adverse event (gastrointestinal irritation, Day 28, resolved within 24 hours, no drug discontinuation) occurred; no serious adverse events were reported. Trial registration: CTRI/2025/06/088636. The study was not funded by any external sources.
CONCLUSIONSNative Himalayan Shilajit 250 mg/day for 49 days was associated with clinically and statistically significant reductions in pain intensity, analgesic consumption, and trigger-point burden in patients with MPS, with a favorable safety profile. These findings warrant confirmation in a larger, randomized, placebo-controlled trial.
]]>2026-08-03doi:10.64898/2026.07.24.26357716Cold Spring Harbor Laboratory2026-08-03
<![CDATA[
Development and Psychometric Validation of the Pelvic Dystonia Severity Scale (PDSS)
]]>
https://www.medrxiv.org/content/10.64898/2026.07.24.26358500v1?rss=1
2026-07-27doi:10.64898/2026.07.24.26358500Cold Spring Harbor Laboratory2026-07-27
<![CDATA[
Assessing Pain Catastrophizing Through Free-Text Responses: A Validation of Large Language Models
]]>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358710v1?rss=1
2026-07-24doi:10.64898/2026.07.22.26358710Cold Spring Harbor Laboratory2026-07-24
<![CDATA[
Palliative Care among People with Advanced Heart Failure: Between Hospital Variation in the US Veterans Administration
]]>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358645v1?rss=1
2026-07-23doi:10.64898/2026.07.22.26358645Cold Spring Harbor Laboratory2026-07-23
<![CDATA[
JAK-STAT pathway inhibition modulates centrally sensitised default mode network hubs in rheumatoid arthritis pain
]]>
https://www.medrxiv.org/content/10.64898/2026.07.12.26356929v1?rss=1
2026-07-14doi:10.64898/2026.07.12.26356929Cold Spring Harbor Laboratory2026-07-14
<![CDATA[
Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study
]]>
https://www.medrxiv.org/content/10.64898/2026.07.11.26357570v1?rss=1
2026-07-14doi:10.64898/2026.07.11.26357570Cold Spring Harbor Laboratory2026-07-14
<![CDATA[
Music listening for chronic pain management: a systematic review, meta-analysis, and evaluation of intervention reporting quality
]]>
https://www.medrxiv.org/content/10.64898/2026.07.08.26357000v1?rss=1
2026-07-13doi:10.64898/2026.07.08.26357000Cold Spring Harbor Laboratory2026-07-13
<![CDATA[
The analgesic effect of ultrasound-guided fascia hydrorelease around the artery for myofascial neck pain: a prospective single-arm interventional study
]]>
https://www.medrxiv.org/content/10.64898/2026.07.01.26356632v1?rss=1
2026-07-10doi:10.64898/2026.07.01.26356632Cold Spring Harbor Laboratory2026-07-10
<![CDATA[
Exploring stakeholder perspectives on the content, delivery, and contextual delivery of shared decision-making for people living with subacromial pain syndrome: a multimethod study with future workshops and interviews
]]>
https://www.medrxiv.org/content/10.64898/2026.07.02.26356879v1?rss=1
2026-07-10doi:10.64898/2026.07.02.26356879Cold Spring Harbor Laboratory2026-07-10
<![CDATA[
Improving palliative care for babies, children, young people and adults from ethnically diverse communities: a qualitative multiple case study
]]>
https://www.medrxiv.org/content/10.64898/2026.07.01.26356998v1?rss=1
2026-07-02doi:10.64898/2026.07.01.26356998Cold Spring Harbor Laboratory2026-07-02
<![CDATA[
Pain Catastrophizing, Pain Self-Efficacy, and their Interaction as Predictors of Health Outcomes in Chronic Pain
]]>
https://www.medrxiv.org/content/10.64898/2026.06.15.26355697v1?rss=1
2026-06-26doi:10.64898/2026.06.15.26355697Cold Spring Harbor Laboratory2026-06-26
<![CDATA[
Fairness-aware, explainable clinical decision support for opioid use disorder risk stratification: development and internal validation of a dual-layer AI system
]]>
https://www.medrxiv.org/content/10.64898/2026.06.23.26356401v1?rss=1
2026-06-26doi:10.64898/2026.06.23.26356401Cold Spring Harbor Laboratory2026-06-26
<![CDATA[
Associations Among Changes in Inflammatory Biomarkers, Pain Intensity, and Health-Related Quality of Life Following a 12-Week Aerobic Exercise Programme in Individuals with Non-Specific Chronic Low Back Pain
]]>
https://www.medrxiv.org/content/10.64898/2026.06.21.26356167v1?rss=1
2026-06-23doi:10.64898/2026.06.21.26356167Cold Spring Harbor Laboratory2026-06-23
<![CDATA[
Supporting people to access social security payments through the Special Rules for End of Life: a qualitative study of the perspectives of patients, carers and health care professionals
]]>
https://www.medrxiv.org/content/10.64898/2026.06.12.26355509v1?rss=1
2026-06-15doi:10.64898/2026.06.12.26355509Cold Spring Harbor Laboratory2026-06-15
<![CDATA[
"We don't complain; it's just part of being a woman": frequency, knowledge, and sociocultural beliefs about dysmenorrhoea in a South African university cohort
]]>
https://www.medrxiv.org/content/10.64898/2026.06.10.26355353v1?rss=1
2026-06-10doi:10.64898/2026.06.10.26355353Cold Spring Harbor Laboratory2026-06-10
<![CDATA[
Safety and Tolerability of Low Intensity Focused Ultrasound to the Anterior Insula in Patients with Fibromyalgia
]]>
https://www.medrxiv.org/content/10.64898/2026.06.01.26354382v1?rss=1
2026-06-09doi:10.64898/2026.06.01.26354382Cold Spring Harbor Laboratory2026-06-09
<![CDATA[
Associations between initial treatments for acute low back pain and opioid use disorder and overdose risk in Medicaid patients
]]>
https://www.medrxiv.org/content/10.64898/2026.06.05.26355003v1?rss=1
50 daily Morphine Milligram Equivalents (MME) (118.1%, 95% CI: 99.2%, 137.0%). Lower-dose, short-duration opioids ([≤] 50 MME, [≤] 7 days) were also associated with elevated risk, though substantially smaller in magnitude (20.8%, 95% CI: 13.8%, 27.9%). In contrast, non-pharmacologic, non-interventional therapies were associated with reduced OUD and overdose diagnosis risk, with physical therapy demonstrating the largest relative reduction of 34.0% (95% CI: -40.9%, -27.1%).
DiscussionIn opioid-naive Medicaid patients with acute low back pain, initial non-pharmacologic treatment was associated with reduced OUD and overdose diagnosis risk. Gabapentinoids and opioids were each associated with increased risk; for opioids, the degree of risk increased with higher doses and durations. These results support guideline recommendations favoring non-pharmacologic treatment as first-line therapy and indicate the importance of cautious prescribing when pharmacologic treatment is considered.
]]>2026-06-08doi:10.64898/2026.06.05.26355003Cold Spring Harbor Laboratory2026-06-08
<![CDATA[
Validation of the Fremantle Perineal Awareness Questionnaire (FrePAQ) in women with Chronic Pelvic Pain
]]>
https://www.medrxiv.org/content/10.64898/2026.06.05.26354913v1?rss=1
2026-06-08doi:10.64898/2026.06.05.26354913Cold Spring Harbor Laboratory2026-06-08
<![CDATA[
Comparing cannabinoid extracts for treating cancer-related symptoms: a randomized placebo-controlled, triple-blind aggregate n-of-1 clinical trial
]]>
https://www.medrxiv.org/content/10.64898/2026.05.31.26354558v1?rss=1
2026-06-02doi:10.64898/2026.05.31.26354558Cold Spring Harbor Laboratory2026-06-02
<![CDATA[
Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey
]]>
https://www.medrxiv.org/content/10.64898/2026.05.29.26354422v1?rss=1
2026-06-01doi:10.64898/2026.05.29.26354422Cold Spring Harbor Laboratory2026-06-01